Overview
To measure the effect of Ivermectin (sub-cutaneous) with or without zinc and Nigella sativa in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.
Description
This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demostrate the antiviral effects of subcutaneous Ivermection with or without zinc and Nigella sativa. in mild to moderate symptomatic patients who consent to randomization following a new diagnosis in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test remained positive..
Eligibility
Inclusion Criteria:
- Nasopharyngeal RT-PCR positive SARS-CoV-2 patient with mild to moderate disease
- Age 18 and above
- BMI 18-28 kg/m
Exclusion Criteria:
- Allergy to any drug
- Co-morbidities: any pre-existing cardiac disease, pulmonary disease
- Arrhythmias
- Pregnancy
- RT-PCR performed >3 days prior to enrollment